Press Conference

Preview of breakthrough research to be formally unveiled at the Dec. 6^th CELL BIO2025 Meeting of American Society of Cell Biologists, Philadelphia.  Nanocrine’s revolutionary RT Chip™ for plasmonic live cell imaging for the first time enables scientists the ability to visualize cell-to-cell signaling as it is occurring in time and space, for single cells or tissue architectures.

FITCI and research partner Nanocrine are proud to be the first to publicly demonstrate a new cellular imaging platform that has the potential to transform the lives of people living with cancer, diabetes and so many other debilitating diseases.  While Nanocrine is currently focused on the vast research market, one can envision how future developments of the technology will enable more precise diagnoses and aid in the development of new therapeutics.  Nanocrine’s advancement in unlocking extracellular communication fills a gap in our understanding of human disease, propelling the development of new therapies for the treatment of wound healing; cancer metastasis; viral pathogenesis; aging & senescence; cardiomyopathies; regenerative and neurodegenerative and other disorders.

Nanocrine’s cutting edge technology was developed through a strong partnership with the U. S. Naval Research Laboratory, supported by FITCI; State of Maryland’s TEDCO; as well as collaborations with the National Institutes of Health (National Cancer Institute & National Center for Advancing Translational Sciences); Virginia Tech; and the Johns Hopkins School of Medicine.